Theranostics Health Avant Completes Acquisitions of Amarantus, Theranostics Health The deals bring together Avant's ovarian cancer diagnostic, Amarantus' multiple sclerosis and Alzheimer's disease assays, and Theranostics' CLIA lab. Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger Premium The deal brings together three firms that have struggled to ramp their test businesses in hopes that the combined outfit will be better positioned to succeed. Avant, Amarantus Diagnostics Add Theranostics Health to Planned Merger Avant and Amarantus, which agreed to merge in January, have now signed a deal to acquire Theranostics Health and its CLIA-certified laboratory. After Expanding Breast Cancer Assay, Theranostics to Launch Colorectal, Pancreatic Cancer Tests Premium The assays, which the company plans to launch at the end of the month, will use RPPA measurements of cancer signaling pathways to guide patient treatment. Theranostics Expands Collaborations with Avera Health Avera Health will offer the TheraLink Assay to its employees and conduct studies to establish the clinical utility of the proteomic panel. Dec 17, 2014 Phosphoproteomic Data from I-SPY 2 IDs Potential New Marker of Patient Response to Neratinib Premium Oct 31, 2014 People in the News: Luis Gutierrez, Glenn Hoke, Valerie Palmieri Premium Oct 29, 2014 People in the News: Luis Gutierrez, Mara Aspinall, Greg Lucier, Valerie Palmieri Premium Nov 15, 2013 GMU's Petricoin Partnering with VC Young on Firm Facilitating Molecular Profiling of Cancer Patients Premium Jul 8, 2013 MD Anderson's Mills Building Cancer Proteome Atlas Using RPPA Data from 70,000-plus Patient Samples Premium Jun 14, 2013 Proteome Sciences Inks Deal with Thermo Exchanging TMT IP for Cash, Aid in SysQuant Clinical Work Premium Jun 7, 2013 Data from Side-Out Breast Cancer Study Suggests Potential of Proteomics for Personalizing Therapy Premium May 3, 2013 Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release Premium Aug 31, 2012 Theranostics Looks for Med Fusion Deal to Aid in Clinical Validation, Payor Access Premium Aug 15, 2012 Med Fusion to Validate Clinical Utility of Theranostics Health Assays Jun 15, 2012 Theranostics Health to Launch Breast Cancer Dx in Early 2013, Raise $5M to $10M in Funding Premium May 4, 2012 Phosphoproteomic Study Shows Resistance to AML Kinase Inhibitors Likely Arises from Multiple Pathways Premium Nov 18, 2011 Phosphoproteomics Study Drives Phase I Trial Testing Pfizer ALK Inhibitor as Breast Cancer Therapy Premium Sep 2, 2011 Theranostics Health Launching Alternative to Formalin for Preserving Phosphoproteomic Tissue Samples Premium Nov 12, 2010 Duke Team Identifies Phosphoprotein Signatures That Could Predict Breast Cancer Risk Premium Nov 5, 2010 Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work Premium Aug 14, 2010 GMU's Petricoin Building Database That Details Activation in Cancer Protein Pathways Premium Jan 28, 2009 Proteins, Front and Center Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.